HR Execs on the Move

Aledade

www.aledade.com

 
Aledade is a new company with an old-fashioned goal: putting doctors back in control of health care. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) – from business and practice transformation services to upfront capital and a cutting-edge technology platform. Our customized solutions – and our continuous, on-the-ground support of our physician partners – will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aledade.com
  • 4550 Montgomery Ave Suite 950
    Bethesda, MD USA 20814
  • Phone: 202.803.7979

Executives

Name Title Contact Details
Nick Kinkaid
Chief Product Officer Profile
Alan Hanley
Vice President Of Product Strategy Profile
Thomas Mullaney
Chief Product Officer Profile
Toby Shum
Senior Vice President Finance Profile
Jessica Gladden
Senior Vice President, People Strategy and Operations Profile

Similar Companies

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Covx Pharmaceuticals

Covx Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

O M I C Usa Inc

O M I C Usa Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.